AI eye on the heart: new tool spots rare amyloidosis earlier
NCT ID NCT07529860
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether an artificial intelligence (AI) program can help doctors identify a rare heart condition called cardiac amyloidosis on routine echocardiograms. The condition causes protein buildup in the heart muscle, leading to heart failure, and is often missed early on. Researchers will enroll 200 adults with thickened heart walls and use the AI tool to flag suspicious cases, which will then be confirmed with specialized scans and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-based echocardiogram (Us2.ai software)
What this could lead to
If successful, this AI tool could help doctors diagnose cardiac amyloidosis earlier and more accurately, leading to timely treatment and better outcomes.
What could go wrong
This is a relatively small, early-stage study (200 participants) focused on detection accuracy, not treatment. The AI may not perform as well in broader, real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••